NCT04197661View on ClinicalTrials.gov

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 25, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

May 22, 2020

Conditions
Healthy Elderly Subjects
Interventions
DRUG

HSK3486

Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

DRUG

HSK3486

Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

DRUG

HSK3486

Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

DRUG

HSK3486

Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

Trial Locations (1)

130021

Phase I Clinical Trial Laboratory, The First Hospital of Jilin University, Changchun

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04197661 - Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects | Biotech Hunter | Biotech Hunter